Delivery Order SPE2DB22D1202-SPE2DB25FVHM3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,552.17. This competitively awarded, non-set-aside delivery order is structured as a firm fixed price contract with an ultimate completion date of July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a $3,304.66 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Vyvanse 30 mg capsules (100-count units). The contract, designated as non-competitive and priced on a firm fixed-price basis, is scheduled for completion by August 4, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,121.45 for Vyvanse 60 mg capsules (100-count units) on August 12, 2025, with completion targeted for August 13, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The delivery order represents a discrete transaction under AmerisourceBergen's broader federal contract portfolio...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The Defense Logistics Agency awarded a delivery order valued at $7,202.90 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) on July 30, 2025, with an ultimate completion date of July 31, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $2,735.43 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 10 mg on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is executed as a child order under AmerisourceBergen's larger prime contract vehicle. The pharmaceutical product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) under a firm fixed-price contract valued at $6,292.03. The order, which is not set-aside for any disadvantaged business category, is scheduled for completion by August 13, 2025, and will be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100-count units) on August 15, 2025, with a ceiling value of $4,198.84. This firm fixed-price delivery order is set to be completed by August 18, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award was competitively awarded without set-aside designation and represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $2,079.25. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,337.70 on July 21, 2025, for the supply of Vyvanse 20 mg capsules (100-count units). This firm fixed-price delivery order, which is expected to be completed by July 22, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Vyvanse is a prescription medication commonly used in...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVHM3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,072.36 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Vyvanse 20 mg capsules (100-count units). This is a firm fixed-price, non-set-aside contract with a completion date of August 18, 2025, and performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor within the Defense Health System's medical supply chain. As a major pharmaceutical distributor, AmerisourceBergen regularly fulfills federal medical procurement requirements through competitive awards, supplying brand-name and generic medications, vaccines, and specialized medical commodities to support military healthcare programs worldwide. The current delivery order for Vyvanse, a prescription stimulant medication commonly used in military healthcare settings, demonstrates the company's ongoing capability to meet urgent pharmaceutical supply needs for the Department of Defense and related federal health systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 8/15/25 |